Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Chorea, Huntington Clinical Trial

Official title: Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Status Active, not recruiting

Clinical Trial Summary

This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.

Clinical Trial Description

After completion of Week 156/early termination visit, participants in the US will be given the option to continue into an extended maintenance period for up to 104 weeks and participants in Canada will have the option to participate in a separate open-label study (Study NBI-98854-HD3022). ;

Related Conditions & MeSH terms

• Chorea
• Chorea, Huntington
• Huntington Disease

• NCT number: NCT04400331
• Study type: Interventional
• Source: Neurocrine Biosciences
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: September 18, 2020
• Completion date: March 2026